The Valley Desk

ArticleCancer research and treatmentPublished

Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Cancer research and treatment
Published
Subject terms
EGFR; c-Met; Non-small cell lung cancer (NSCLC); Tyrosine Kinase Inhibitors
PubMed ID
41927036
Added to directory
Source checked

Report a correction or request removal